BLA 761224 · Astrazeneca Ab
Tezspire
Tezepelumab-Ekko · Subcutaneous · Thymic Stromal Lymphopoietin Blocker
NovelPriority reviewCDER novel approval, Dec 17, 2021: To treat severe asthma as an add-on maintenance therapy
Last checked: Nov 20, 2026Latest source record: Oct 17, 2025 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2021
Dec 17, 2021
Approved uses
3
Original approval plus efficacy supplements
Registered trials
49
21 Phase 3, 12 recruiting
FAERS reports
6,931
3,128 serious, 255 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
What it is approved for
From the label in effect Oct 17, 2025.
TEZSPIRE is a thymic stromal lymphopoietin (TSLP) blocker, human monoclonal antibody (IgG2λ), indicated: • for the add-on maintenance treatment of adult and pediatric patients aged 12 years and older with severe asthma. ( 1.1 ) Limitations of Use: Not for relief of acute bronchospasm or status asthmaticus. ( 1.1 ) • for the add-on maintenance treatment of adult and pediatric patients aged 12 years and older with inadequately controlled chronic rhinosinusitis with nasal polyps (CRSwNP). ( 1.2 ) 1.1 Asthma TEZSPIRE is indicated for the add-on maintenance treatment of adult and pediatric patients aged 12 years and older with severe asthma. Limitations of Use: TEZSPIRE is not indicated for the relief of acute bronchospasm or status asthmaticus. 1.2 Chronic Rhinosinusitis with Nasal Polyps TEZSPIRE is indicated for the add-on maintenance treatment of adult and pediatric patients aged 12 years and older with inadequately controlled chronic rhinosinusitis with nasal polyps (CRSwNP).
Mechanism: Tezepelumab-ekko is a thymic stromal lymphopoietin (TSLP) blocker, human monoclonal antibody IgG2λ that binds to human TSLP with a dissociation constant of 15.8 pM and blocks its interaction with the heterodimeric TSLP receptor. TSLP is a cytokine mainly derived from epithelial cells and occupies an upstream position in inflammatory cascades. Airway and mucosal inflammation are important components of the pathogenesis of asthma and CRSwNP. Multiple cell types (e.g., mast cells, eosinophils, neutrophils, macrophages, lymphocytes, ILC2 cells) and mediators (e.g., histamine, eicosanoids,...
Therapeutic areas: Respiratory
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- Oct 17, 2025 Supplement 6 · Efficacy LabelLetter
- Feb 1, 2023 Supplement 1 · Efficacy LetterLabel
- Dec 17, 2021 Original approval · Type 1 - New Molecular Entity · priority review NovelLabelLetterReview
1 products under this application
- TEZSPIRE · TEZEPELUMAB-EKKO 210MG/1.91ML(110MG/ML) · SOLUTION, SUBCUTANEOUS · Prescription
Clinical trials
Interventional ClinicalTrials.gov studies with "Tezepelumab" as an intervention, any sponsor and status, largest first.
- Study to Evaluate Tezepelumab in Adults & Adolescents With Severe Uncontrolled AsthmaPivotal-lookingCompleted
AstraZenecaAstraZeneca (AZN)
NCT03347279 · 1,061 participants · Start Nov 23, 2017 · Primary completion Sep 8, 2020
Drug: Experimental: Tezepelumab · For: Asthma
Sites: Dothan, Alabama; Foley, Alabama; Gilbert, Arizona · 289 sites in all
- A Study to Investigate the Efficacy and Safety of Tezepelumab in Adult Participants With Moderate to Very Severe COPD (D5241C00006)Pivotal-lookingRecruiting
AstraZenecaAstraZeneca (AZN)
NCT06883305 · 990 participants (planned) · Start Mar 18, 2025 · Primary completion Mar 13, 2029
Drug: Tezepelumab · For: Chronic Obstructive Pulmonary Disease (COPD)
Sites: Foley, Alabama; Mobile, Alabama; Sheffield, Alabama · 305 sites in all
- A Study to Investigate the Efficacy and Safety of Tezepelumab in Adult Participants With Moderate to Very Severe COPD (D5241C00007)Pivotal-lookingRecruiting
AstraZenecaAstraZeneca (AZN)
NCT06878261 · 990 participants (planned) · Start Mar 25, 2025 · Primary completion Mar 13, 2029
Drug: Tezepelumab · For: Chronic Obstructive Pulmonary Disease (COPD)
Sites: Birmingham, Alabama; Cullman, Alabama; Phoenix, Arizona · 284 sites in all
- Extension Study to Evaluate the Safety and Tolerability of Tezepelumab in Adults and Adolescents With Severe, Uncontrolled AsthmaPivotal-lookingCompleted
AstraZenecaAstraZeneca (AZN)
NCT03706079 · 951 participants · Start Jan 7, 2019 · Primary completion Oct 26, 2021
Drug: Tezepelumab · For: Asthma
Sites: Dothan, Alabama; Gilbert, Arizona; Bakersfield, California · 180 sites in all
- Compare the Efficacy and Safety of QL2302 Versus Tezspire® in Severe AsthmaPivotal-lookingNot yet recruiting
Qilu Pharmaceutical Co., Ltd.Industry
NCT07302516 · 636 participants (planned) · Start Dec 25, 2025 · Primary completion Dec 2028
Drug: tezepelumab (Arm1&Arm2) · For: Asthma
- Study to Evaluate the Efficacy and Safety of MEDI9929 (AMG 157) in Adult Subjects With Inadequately Controlled, Severe AsthmaPivotal-lookingCompleted
MedImmune LLCAstraZeneca (AZN)
NCT02054130 · 584 participants · Start Dec 13, 2013 · Primary completion Dec 12, 2016
Drug: Placebo; MEDI9929 70 mg and 2 more · For: Asthma
Sites: Los Angeles, California; Miami, Florida; Oviedo, Florida · 107 sites in all
- Efficacy and Safety of Tezepelumab in Participants With Severe Chronic Rhinosinusitis With Nasal PolyposisPivotal-lookingCompleted
AstraZenecaAstraZeneca (AZN)
NCT04851964 · 416 participants · Start Apr 22, 2021 · Primary completion Sep 23, 2024
Drug: Experimental: Tezepelumab; Mometasone furoate or equivalent intranasal corticosteroid · For: Chronic Rhinosinusitis With Nasal Polyps
Sites: Birmingham, Alabama; Bakersfield, California; Newport Beach, California · 112 sites in all
- Study to Evaluate Tezepelumab in Adults With Severe Uncontrolled AsthmaPivotal-lookingCompleted
AstraZenecaAstraZeneca (AZN)
NCT03927157 · 405 participants · Start Jun 14, 2019 · Primary completion May 24, 2024
Drug: Experimental: Tezepelumab · For: Asthma
Sites: Baotou, China; Beijing, China; Changchun, China · 72 sites in all
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- asthma1,067
- dyspnoea649
- drug ineffective552
- arthralgia551
- product dose omission issue355
- cough342
- pneumonia294
- fatigue273
- headache259
- back pain242
- rash239
- pain233
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2018 | 1 |
| 2019 | 4 |
| 2020 | 8 |
| 2021 | 7 |
| 2022 | 588 |
| 2023 | 1,252 |
| 2024 | 1,589 |
| 2025 | 1,785 |
| 2026 | 1,697 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Part D: Tezspire (Tezepelumab-Ekko)
2024 spending
$184M
Beneficiaries
6,219
41,254 claims
Per beneficiary
$29,549
$2,241.12 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $0 |
| 2021 | $0 |
| 2022 | $25,810,045 |
| 2023 | $88,238,002 |
| 2024 | $183,765,288 |
Part B: Tezspire (Tezepelumab-Ekko) · HCPCS J2356
2024 spending
$218M
Beneficiaries
7,618
59,000 claims
Per beneficiary
$28,676
2024 ASP limit $18.18 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $0 |
| 2021 | $0 |
| 2022 | $31,796,362 |
| 2023 | $138,128,729 |
| 2024 | $218,453,021 |
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Tezepelumab in Adults with Severe Chronic Rhinosinusitis with Nasal Polyps.
Lipworth BJ, Han JK, Desrosiers M, et al. · N Engl J Med 2025 · Randomized Controlled Trial, Multicenter Study
- Tezepelumab in Adults and Adolescents with Severe, Uncontrolled Asthma.
Menzies-Gow A, Corren J, Bourdin A, et al. · N Engl J Med 2021 · Clinical Trial, Phase III, Multicenter Study
- Biologic Therapies for Chronic Obstructive Pulmonary Disease: A Systematic Review and Network Meta-Analysis of Randomized Controlled Trials.
Pitre T, Lupas D, Mah J, et al. · COPD 2025 · Systematic Review, Network Meta-Analysis
- Tezepelumab in Adults with Uncontrolled Asthma.
Corren J, Parnes JR, Wang L, et al. · N Engl J Med 2017 · Clinical Trial, Phase II, Comparative Study
- Efficacy and safety of tezepelumab versus placebo in adults with moderate to very severe chronic obstructive pulmonary disease (COURSE): a randomised, placebo-controlled, phase 2a trial.
Singh D, Brightling CE, Rabe KF, et al. · Lancet Respir Med 2025 · Randomized Controlled Trial, Clinical Trial, Phase II
- Biologic agents licensed for severe asthma: a systematic review and meta-analysis of randomised controlled trials.
Kyriakopoulos C, Gogali A, Markozannes G, et al. · Eur Respir Rev 2024 · Systematic Review, Meta-Analysis
Sponsor: AstraZeneca
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.